Atezolizumab Injection [Tecentriq]

Phase 2

Roche Holding AG (RHHBY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

RHHBYPhase 2$316.4B

Atezolizumab Injection [Tecentriq] Phase 2 Est. Readout

Atezolizumab Injection [Tecentriq]• Bladder Cancer39

Feb 2027~Confirmed

CT.gov

00%

Competitive Landscape

3 competitors in Bladder Cancer

PHOBlue Light Cystoscopy Systems

PHO.OLBlue Light Cystoscopy Systems

PFEenfortumab vedotin

Approved

View Full Landscape

Drug Information

Target Indication

Bladder Cancer

Clinical Trial

NCT04186013

Last updated: 8/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

Pegylated Interferon/ribavirinPhase 3

Chronic Hepatitis C

Trastuzumab in combination with pertuzumabPhase 3

Haematological Malignancy

PEGIntron plus ribavirinPhase 3

Chronic Hepatitis C Virus Infection

background treatmentPhase 3

Tubular Breast Cancer Stage II

tenecteplasePhase 3

Myocardial Infarction

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts